The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian multicenter study

J. Kondás, L. Kiss, A. Határ, A. Kiss, T. Lukács, P. Szeldeli, F. Törzsök, I. Bodrogi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We evaluated the prophylactic efficacy of instillations of intravesical mitomycin C in 57 patients with primary superficial bladder cancer in a multicenter clinical trial. After complete transurethral resection of Ta-T1 G1-G2 transitional cell bladder carcinomas, patients were treated with mitomycin 40 mg/50 ml saline of 15 instillations for 12 months. Most of the complications were mild and transient but two patients dropped out of the trial because of moderate side effects. Fifty-one patients were evaluable. We observed tumour recurrences in six patients (11.8%) during a median follow-up of 44.5 months. The recurrences were treated by transurethral resection. There was no muscle invasive progression in the recurrences. Our investigations confirm the effectiveness of mitomycin C in the treatment of patients with superficial bladder cancer.

Original languageEnglish
Pages (from-to)451-456
Number of pages6
JournalInternational Urology and Nephrology
Volume31
Issue number4
DOIs
Publication statusPublished - 1999

Fingerprint

Mitomycin
Urinary Bladder Neoplasms
Multicenter Studies
Recurrence
Intravesical Administration
Transitional Cell Carcinoma
Urinary Bladder
Clinical Trials
Muscles
Neoplasms

ASJC Scopus subject areas

  • Nephrology
  • Urology
  • Geriatrics and Gerontology

Cite this

The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian multicenter study. / Kondás, J.; Kiss, L.; Határ, A.; Kiss, A.; Lukács, T.; Szeldeli, P.; Törzsök, F.; Bodrogi, I.

In: International Urology and Nephrology, Vol. 31, No. 4, 1999, p. 451-456.

Research output: Contribution to journalArticle

Kondás, J. ; Kiss, L. ; Határ, A. ; Kiss, A. ; Lukács, T. ; Szeldeli, P. ; Törzsök, F. ; Bodrogi, I. / The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian multicenter study. In: International Urology and Nephrology. 1999 ; Vol. 31, No. 4. pp. 451-456.
@article{d9f8b495c14f4eaea3ab5253e926a70f,
title = "The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian multicenter study",
abstract = "We evaluated the prophylactic efficacy of instillations of intravesical mitomycin C in 57 patients with primary superficial bladder cancer in a multicenter clinical trial. After complete transurethral resection of Ta-T1 G1-G2 transitional cell bladder carcinomas, patients were treated with mitomycin 40 mg/50 ml saline of 15 instillations for 12 months. Most of the complications were mild and transient but two patients dropped out of the trial because of moderate side effects. Fifty-one patients were evaluable. We observed tumour recurrences in six patients (11.8{\%}) during a median follow-up of 44.5 months. The recurrences were treated by transurethral resection. There was no muscle invasive progression in the recurrences. Our investigations confirm the effectiveness of mitomycin C in the treatment of patients with superficial bladder cancer.",
author = "J. Kond{\'a}s and L. Kiss and A. Hat{\'a}r and A. Kiss and T. Luk{\'a}cs and P. Szeldeli and F. T{\"o}rzs{\"o}k and I. Bodrogi",
year = "1999",
doi = "10.1023/A:1007155026151",
language = "English",
volume = "31",
pages = "451--456",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - The effect of intravesical mitomycin C on the recurrence of superficial (Ta-T1) bladder cancer. A Hungarian multicenter study

AU - Kondás, J.

AU - Kiss, L.

AU - Határ, A.

AU - Kiss, A.

AU - Lukács, T.

AU - Szeldeli, P.

AU - Törzsök, F.

AU - Bodrogi, I.

PY - 1999

Y1 - 1999

N2 - We evaluated the prophylactic efficacy of instillations of intravesical mitomycin C in 57 patients with primary superficial bladder cancer in a multicenter clinical trial. After complete transurethral resection of Ta-T1 G1-G2 transitional cell bladder carcinomas, patients were treated with mitomycin 40 mg/50 ml saline of 15 instillations for 12 months. Most of the complications were mild and transient but two patients dropped out of the trial because of moderate side effects. Fifty-one patients were evaluable. We observed tumour recurrences in six patients (11.8%) during a median follow-up of 44.5 months. The recurrences were treated by transurethral resection. There was no muscle invasive progression in the recurrences. Our investigations confirm the effectiveness of mitomycin C in the treatment of patients with superficial bladder cancer.

AB - We evaluated the prophylactic efficacy of instillations of intravesical mitomycin C in 57 patients with primary superficial bladder cancer in a multicenter clinical trial. After complete transurethral resection of Ta-T1 G1-G2 transitional cell bladder carcinomas, patients were treated with mitomycin 40 mg/50 ml saline of 15 instillations for 12 months. Most of the complications were mild and transient but two patients dropped out of the trial because of moderate side effects. Fifty-one patients were evaluable. We observed tumour recurrences in six patients (11.8%) during a median follow-up of 44.5 months. The recurrences were treated by transurethral resection. There was no muscle invasive progression in the recurrences. Our investigations confirm the effectiveness of mitomycin C in the treatment of patients with superficial bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=0033451777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033451777&partnerID=8YFLogxK

U2 - 10.1023/A:1007155026151

DO - 10.1023/A:1007155026151

M3 - Article

VL - 31

SP - 451

EP - 456

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 4

ER -